ArticleBiotechnology for biofuels and bioproducts2025
High-yield zeaxanthin production in Chlamydomonas reinhardtii via advanced metabolic pathway engineering.
Article in Biotechnology for biofuels and bioproducts, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- CRISPR-enhanced microalgae for carbon sequestration and carotenoid production: opportunities and fundamental constraints.Bioresources and bioprocessing · 2026Review
- Antioxidant Compounds in Microalgae and Cyanobacteria: A Sustainable Source of Bioactive Molecules.Marine drugs · 2026Review
- Zeaxanthin-Producing Winogradskyella schleiferi Strains.Journal of basic microbiology · 2026Article
- Advances in Sustainable Lutein Production: Sources, Technologies, and Functional Applications.Foods (Basel, Switzerland) · 2026Review
- CRISPR-enhanced microalgae biosynthesis: a promising approach for future functional feed ingredients.Journal of animal science and biotechnology · 2026Review
- Synthetic Biology and Metabolic Engineering of Microalgae for Sustainable Lipid and Terpenoid Production: An Updated Perspective.Plant biotechnology journal · 2026Review
- Engineering Microalgae for Enhanced Astaxanthin Production: Integrating Metabolic Pathways and Nano-Biotechnologies.Marine drugs · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundZeaxanthin is a yellow xanthophyll naturally found in plants and algae, where it plays a crucial role in light absorption and photoprotection. In mammals, ingestion of zeaxanthin through the diet is essential as it accumulates in the retina where it absorbs excessive blue light to protect photoreceptors from photooxidative stress. Chlamydomonas reinhardtii is an established model organism for pigment biosynthesis and bioengineering. Previous studies developed double knockout mutants (dzl) using CRISPR-Cas9 to eliminate ZEP and LCYE genes, achieving zeaxanthin production up to 6.84 mg/L with medium optimization. However, these approaches have not explored additional enzyme overexpression strategies combined with advanced cultivation techniques, leaving significant potential for enhanced zeaxanthin biosynthesis unexplored.
resultsIn this study, we strategically enhanced zeaxanthin biosynthesis in C. reinhardtii by genome editing to knockout competing pathways coupled with overexpression of rate limiting enzymes and optimization of cultivation for efficient biomass accumulation. We employed the knockout of lycopene epsilon cyclase (LCYE; dL mutant), which resulted in a 2.83-fold increase in zeaxanthin levels. Additionally, knocking out zeaxanthin epoxidase (ZEP, dLZ mutant) redirected metabolic flux towards zeaxanthin biosynthesis, further enhancing its accumulation by 14.07-fold. Overexpression of β-carotene hydroxylase (CHYB, dLZ_C strains) enabled efficient hydroxylation of β-carotene and increasing zeaxanthin concentration further by1.80-fold without compromising growth. In addition, elevated acetate concentrations supported mixotrophic growth and resulted in a zeaxanthin yield of 21.68 ± 0.90 mg/L, threefold higher compared to previously reported values and a culminated 190-fold increase compared to the parental strain (UVM4) grown in standard medium.
conclusionOur study developed a zeaxanthin-producing mutant strain by integrating gene modification, gene overexpression, and culture optimization. Among various green microalgae, the engineered strain dLZ_C demonstrated notable zeaxanthin productivity, reaching 6.70 mg/L/day over a period of 3 days, suggesting its potential as a candidate for industrial production. Its improved efficiency may offer advantages for large-scale applications in microalgal-based zeaxanthin production. Additionally, these findings indicate that Chlamydomonas reinhardtii could serve as a viable and sustainable platform for biotechnological applications in the health, nutrition, and biotechnology sectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.